In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer: Innovation at the Lowest Cost

Executive Summary

Pfizer's economic figuring goes something like this: an internally discovered drug, or one licensed for relatively little money at an early stage of development, can nonetheless be considerably less profitable than one in-licensed when it is nearly ready for NDA filing, even if the drug costs a small fortune in cash and quids.

You may also be interested in...



Ironwood Pharmaceuticals: Independent for the Long Haul

Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.

Ironwood Pharmaceuticals: Independent for the Long Haul

Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.

Canary in the Coalmine: Pfizer R&D

In an interview, Pfizer's head of R&D, John LaMattina, discusses R&D's position as the part of the company most vulnerable to cuts in response to weakening sales. Among other issues, LaMattina discusses Pfizer's increasing interest in large molecules, specialist markets and combination products, and the role external research will play in filling a pipeline facing significant near-term generic pressures. He also details Pfizer's advantages of scale, particularly in developing portfolios of products in individual disease areas for sale to major customers interested in large discounted, disease-managed product packages.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel